T. Rowe Price Group

Nuro, Inc. is a technology company based in Mountain View, California, that specializes in the development of self-driving vehicles specifically designed for local goods transportation. Incorporated in 2016, Nuro aims to transform local commerce through its fleet of fully autonomous, electric vehicles that facilitate the delivery of a wide range of products, including food and pharmaceuticals. By enabling retailers to efficiently and safely deliver goods to customers, Nuro enhances the convenience of local commerce and meets the growing demand for autonomous delivery solutions.

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Epirus, Inc. is a technology company based in Hawthorne, California, specializing in the design and development of advanced defense systems that utilize artificial intelligence and directed energy. Founded in 2018, the company focuses on creating solid-state, software-defined high-power microwave solutions aimed at countering unmanned aircraft systems and other asymmetric threats. Its flagship product, ELECTROMAGNETIC PULSE, serves as a counter-infrastructure solution that can simultaneously target multiple threats, effectively neutralizing drones and swarms. By integrating AI and machine learning with advanced electronics, Epirus enhances the detection and tracking of objects of interest, offering innovative capabilities in electronic warfare and power management for both defense and commercial sectors.

Eikon Therapeutics, Inc. is a biopharmaceutical company based in Hayward, California, focused on developing innovative treatments for chronic and life-threatening diseases. Founded in 2019, the company employs advanced super-resolution microscopy and live-cell imaging techniques to discover drugs targeting previously intractable proteins. By integrating biology, engineering, and chemistry, Eikon Therapeutics aims to enhance the understanding of cellular processes and improve drug discovery efficiency. Its proprietary platforms allow for the sensitive identification of compound-protein interactions, enabling the direct measurement of how chemical compounds affect individual proteins in live cells. This novel approach seeks to unlock new therapeutic opportunities and expand the company's pipeline of potential medications.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

SandboxAQ is a company that develops artificial intelligence and quantum technology solutions aimed at addressing complex business and scientific challenges. By integrating expertise from multiple disciplines, including physics, computer science, and mathematics, the company creates Large Quantitative Models and AI sensing applications tailored for various industries. Its offerings are designed to provide practical solutions in sectors such as financial services, healthcare, telecommunications, and cybersecurity. Through its innovative software, SandboxAQ enables clients to tackle significant computational challenges and advance their technological capabilities.

nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.

Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of oral and injectable treatment options, including incretin, non-incretin, and combination therapies. These treatments are designed to address multiple therapeutic targets, positioning Metsera to meet the evolving demands of the weight loss treatment landscape. Additionally, Metsera integrates proprietary health technology tools to provide personalized care, enhancing the effectiveness of its therapeutic offerings.

Seaport Therapeutics is a clinical stage biopharmaceutical company focused on developing innovative neuropsychiatric medicines for patients with significant unmet needs. The company's approach emphasizes the creation of treatments that offer oral bioavailability, which allows the medications to bypass first-pass metabolism. This method aims to reduce hepatotoxicity and other adverse side effects commonly associated with neuropsychiatric treatments. By addressing these critical issues, Seaport Therapeutics seeks to improve the quality of life for individuals living with neuropsychiatric disorders.

Lightmatter specializes in developing photonic chips that leverage light for data processing and communication, significantly enhancing the speed and efficiency of artificial intelligence computations. By utilizing integrated optical technology, the company designs processors that accelerate key operations in neural networks through programmable photonic elements, which are fabricated alongside traditional transistors. This innovative approach allows for improved performance in applications such as image recognition and natural language processing while maintaining low power consumption. Lightmatter's technology primarily serves sectors including artificial intelligence, cloud computing, and telecommunications, positioning the company as a leader in light-based computing solutions.

Form Energy, Inc. specializes in the development of long-duration energy storage systems aimed at enhancing the reliability of renewable energy sources such as wind and solar. Founded in 2017 and based in Somerville, Massachusetts, the company focuses on creating low-cost battery systems, including its innovative iron-air battery technology, which allows for energy storage over extended periods. This capability enables the dispatch of renewable energy throughout the year, effectively replacing traditional fossil fuel-based generation and contributing to the decarbonization of the electric grid. Additionally, Form Energy offers Formware, a capacity expansion software tool designed to optimize energy management. The company's technological advancements are rooted in research from MIT and are supported by various investors committed to sustainable energy solutions.

KoBold Metals operates as an AI-powered mineral exploration company focused on discovering materials essential for the electric vehicle and renewable energy sectors. The company utilizes advanced software that aggregates and structures extensive scientific datasets, including geochemical, geophysical, and geological information. By applying various analytical techniques such as ensemble machine learning and computer vision, KoBold predicts subsurface compositions in a statistically valid manner. This innovative approach enhances the exploration efficiency for mineral resources, particularly cobalt, which is crucial for the electric vehicle industry. By merging ore-deposit science with big data and scientific computing, KoBold Metals aims to identify new sources of cobalt and support the sustainable supply chain for emerging technologies.

Aktis Oncology is a biotechnology company focused on developing targeted radiopharmaceuticals for the treatment of various solid tumor cancers. The company has created proprietary platforms that generate tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered to achieve high penetration into tumors and prolonged residence time, allowing for effective tumor elimination while reducing side effects associated with treatment. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing the precision of cancer treatment.

ArsenalBio is a programmable cell therapy company established in 2019, focused on developing effective and accessible immune cell therapies, primarily targeting cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create a new paradigm for discovering and developing immune cell therapies. ArsenalBio's innovative approach aims to enhance the efficacy and safety of T-cell therapies while reducing costs for providers and broadening patient access. By employing a full-stack research and development engine, ArsenalBio generates multifunctional T-cell medicines through the precise insertion of large synthetic DNA sequences, enabling clinicians to utilize next-generation autologous T-cell therapies to combat cancer more effectively.

MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Established in 2018, the company focuses on creating peptides aimed at treating genetic diseases that affect glandular hormones, which play a crucial role in the body’s chemical messaging system. By targeting conditions with inadequate treatment options, MBX Biosciences is dedicated to discovering, developing, and commercializing innovative endocrine therapeutics.

Kestra Medical Technologies, Inc. specializes in the development and manufacturing of wearable medical devices designed for monitoring and managing acute medical conditions. Founded in 2014 and based in Kirkland, Washington, the company offers solutions that collect, communicate, and store patient performance data, enabling both real-time and retrospective analysis. Among its products are wearable cardioverter defibrillators, which aim to prevent sudden cardiac death and facilitate cardiac recovery in at-risk patients. Kestra Medical Technologies focuses on creating intuitive and mobile diagnostic and therapeutic technologies that support healthcare providers and enhance patient care.

Waymo is a self-driving technology company focused on enhancing mobility by creating safe and efficient transportation solutions. Established from advancements in Google's research since 2009, Waymo aims to improve the movement of people and goods through its innovative software and sensor technology. In 2015, the company marked a significant milestone by conducting the world's first fully autonomous trip on public roads in a vehicle devoid of traditional driving controls. Waymo continually refines its technology through extensive simulation testing, accumulating over one billion miles of virtual testing annually, while its autonomous vehicles have logged more than two million miles on public roads in four U.S. cities. By employing integrated sensors and artificial intelligence, Waymo's technology is designed to detect various obstacles such as pedestrians, cyclists, and road conditions, ensuring a safe and convenient on-demand travel experience for users.

Clio is a provider of a cloud-based practice management platform tailored specifically for solo practitioners and small law firms. Its suite of web-based tools streamlines essential functions such as client management, billing, administration, and communication. By enhancing these day-to-day processes, Clio enables legal professionals to efficiently manage their cases and improve client collaboration. The platform is designed to simplify the complexities of legal practice, making it an essential resource for modern law firms seeking to optimize their operations.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

PolicyBazaar Insurance Brokers Private Limited is an online platform based in Gurugram, India, that offers a range of insurance services, including life, health, car, two-wheeler, travel, and home insurance. Founded in 2014, the company provides a comparison portal and mobile application that enable users to analyze and compare various insurance products based on coverage, premiums, benefits, and exclusions. By doing so, PolicyBazaar helps consumers make informed decisions regarding their insurance needs. The platform also includes tools and calculators to assist users in estimating their insurance requirements. With a focus on creating awareness about financial impacts related to death, disease, and damage, PolicyBazaar generates the majority of its revenue from its insurance services segment, which includes insurance broker services.

Sila is a battery materials company founded in 2011 and headquartered in California, United States. It specializes in manufacturing energy-dense lithium-ion batteries designed for electric vehicles and consumer electronics. Sila collaborates with automotive original equipment manufacturers (OEMs) to accelerate product development and partners with battery manufacturers to enhance commercial cell production. The company focuses on providing advanced battery materials that improve energy storage capabilities, enabling the production of small, light, and long-lasting devices. By offering superior performance and quality control, Sila aims to facilitate the mass adoption of affordable, long-range electric vehicles while maintaining safety and cycle life standards.

Kardium Inc. is a medical solutions company based in Burnaby, Canada, specializing in the diagnosis and treatment of atrial fibrillation (AF). Founded in 2007, the company has developed the Globe Mapping and Ablation System, which streamlines AF treatment by integrating single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation into a single catheter. This advanced system aids medical practitioners in diagnosing and treating cardiovascular diseases by providing detailed electrophysiological mapping and the ability to ablate cardiac tissue using radio-frequency energy. Kardium's team comprises experts in medicine, engineering, and research, ensuring a robust foundation for innovation in medical device technology.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies aimed at overcoming cancer treatment resistance and improving patient access to potentially curative options. The company aims to enhance treatment outcomes by addressing the limitations of existing therapies, which currently provide curative benefits to less than half of cancer patients. Its lead program, CRG-022, is a novel CAR T-cell product candidate that targets CD22, a tumor antigen prevalent in many B-cell malignancies. By tackling issues such as limited durability, safety concerns, and supply chain obstacles, Cargo Therapeutics is committed to advancing innovative solutions that make effective cancer treatments more accessible to patients.

BrightView Holdings Inc is a prominent provider of commercial landscaping services in the United States, employing over 18,000 individuals. The company specializes in a wide range of services, including landscape maintenance, enhancements, tree care, and landscape development. BrightView operates through two main segments: Maintenance Services and Development Services. Maintenance Services are primarily self-performed via a national branch network, focusing on route-based operations, while Development Services involve the design, coordination, and installation of landscapes for notable corporate, athletic, and university complexes. Serving a diverse clientele that includes corporate properties, public parks, healthcare facilities, educational institutions, and golf courses, BrightView is committed to creating exceptional landscapes that enhance the quality of life in the communities it serves.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, that focuses on developing innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Founded in 2018, the company is working on a small-molecule inhibitor designed to target the underlying causes of this progressive lung disease. The treatment aims to not only halt the progression of IPF but also has the potential to reverse its effects, offering healthcare professionals a new avenue for precision treatments in managing terminal conditions. Endeavor BioMedicines strives to improve patient outcomes and enhance quality of life for those affected by this challenging illness.

Obsidian Therapeutics develops innovative cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Founded in 2015 and based in Cambridge, Massachusetts, the company focuses on creating next-generation therapies that utilize pharmacologic operating systems to provide precise control over protein activity within cells. This technology allows for the development of adoptive cell therapies with advanced functionalities that can be managed by physicians using simple, safe, and orally active medications. By offering improved control over treatment, Obsidian Therapeutics aims to provide better outcomes for patients compared to existing cell therapy options.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Lambda is a technology company specializing in deep-learning infrastructure. It provides cloud computing services tailored for large-scale artificial intelligence training and inference. The company offers servers and workstations pre-configured with popular machine learning frameworks, allowing clients to simplify and accelerate the development of complex AI models for tasks such as natural language processing and drug discovery. Lambda's product range includes on-premises GPU hardware and cloud-hosted GPUs, empowering AI engineers to construct, test, and deploy AI products efficiently and securely at scale.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

ProfoundBio is a clinical-stage biotechnology company dedicated to creating innovative antibody-based therapeutics aimed at treating cancer. Utilizing proprietary technology platforms, the company has developed a diverse pipeline of antibody-drug conjugate (ADC) candidates targeting both solid tumors and hematological malignancies. These drug candidates are currently in various stages of discovery, preclinical, and clinical development. ProfoundBio's focus is on harnessing the immune system to provide patients with more effective treatments that have the potential for curative outcomes.

Lilac Solutions, Inc. is a mining technology company focused on lithium extraction, providing innovative technology and services to lithium producers. The company specializes in ion exchange beads and continuous brine processing systems, which enable the efficient production of high-purity lithium solutions from various brine resources. This technology, grounded in ion-exchange theory, allows lithium producers to enhance project development, improve lithium recovery rates, and optimize operational efficiency while also minimizing costs and environmental impact. Lilac Solutions serves industries such as electric vehicles and renewable energy storage. Incorporated in 2015, the company is headquartered in Oakland, California.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Apiture, Inc. is a financial technology company that specializes in developing digital banking solutions for banks and credit unions across the United States. Established in 2017 and headquartered in Wilmington, North Carolina, with an additional office in Austin, Texas, Apiture offers products such as Apiture Open, which facilitates account openings for checking, savings, CDs, and loans, and Apiture Xpress, an integrated digital banking solution for both consumer and business account holders. The company focuses on empowering financial institutions by providing a flexible platform that combines consumer and business banking, account opening, and data intelligence. Through its innovative approach, Apiture aims to enhance the capabilities of its clients, enabling them to serve their customers effectively while maintaining the personalized touch of community banks at a larger scale. Apiture operates as a subsidiary of First Data Corporation and has formed a strategic alliance with DefenseStorm, Inc.

Stash develops a personal finance application to combine banking, investing, and advice into one platform. Its application's services include personal investment accounts, retirement accounts, and custodial accounts for minors. It also provides the option to buy fractional shares of stocks, bonds, and funds with no add-on trading commissions to help users save small sums of money and make micro-investments.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Databricks Inc. is a technology company that provides a unified data analytics cloud platform designed to facilitate data engineering and collaborative data science. The company offers a comprehensive suite of tools, including a just-in-time data platform that simplifies data integration, real-time experimentation, and deployment of production applications for developers and data scientists. Key products include Databricks Delta, which combines the capabilities of data warehouses with low-latency streaming, MLflow for managing the machine learning lifecycle, and Delta Lake for handling batch and streaming data. Databricks serves a diverse range of industries, including advertising, healthcare, manufacturing, and telecommunications, and has established strategic partnerships with various organizations to enhance its offerings. Founded in 2013, Databricks is headquartered in San Francisco, California, with additional offices in London, Amsterdam, and Bengaluru.

Sortera Alloys manufactures low-cost, high-quality metal alloys for domestic manufacturing using its artificial intelligence technology. Sortera Alloys is a company based in Fort Wayne, Indiana, and was established in 2020.

Redwood Materials, Inc. is a Nevada-based company focused on advancing sustainable battery recycling technologies to create a circular supply chain for lithium-ion batteries. Founded by JB Straubel in 2017, Redwood specializes in the recycling and processing of end-of-life batteries and electronics to recover critical materials such as lithium, nickel, cobalt, copper, and various metals. The company currently receives approximately 10 GWh of used batteries annually and aims to scale its production of anode and cathode materials to 100 GWh by 2025, sufficient for manufacturing over one million electric vehicles each year. By providing environmentally sound solutions for recycling and refining, Redwood supports industries including electric vehicles, renewable energy storage, and consumer electronics, thereby contributing to a reduction in the environmental impact of battery production and usage.

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing innovative small-molecule therapies for neurological disorders. The company focuses on understanding the intricate biology of neuronal receptor complexes, which are essential for proper neuronal function and signaling. By mapping and targeting these receptor systems, Rapport Therapeutics aims to create precision medicines that can effectively address the unmet needs of patients suffering from central nervous system disorders. Through its foundational research, the company seeks to transform treatment options and improve outcomes for individuals with these challenging conditions.

Genesis Therapeutics Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing small molecule drug candidates aimed at treating patients with severe and debilitating disorders. Established in 2019, the company harnesses a proprietary artificial intelligence platform that employs advanced deep neural networks and biophysical simulation techniques to enhance drug discovery and molecular design. By combining these innovative technologies with a scalable computing infrastructure, Genesis Therapeutics aims to improve the efficiency and accuracy of molecular research. This approach not only facilitates the generation and analysis of novel drug candidates but also holds the potential to significantly advance clinical outcomes in the medical community.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

KoBold Metals operates as an AI-powered mineral exploration company focused on discovering materials essential for the electric vehicle and renewable energy sectors. The company utilizes advanced software that aggregates and structures extensive scientific datasets, including geochemical, geophysical, and geological information. By applying various analytical techniques such as ensemble machine learning and computer vision, KoBold predicts subsurface compositions in a statistically valid manner. This innovative approach enhances the exploration efficiency for mineral resources, particularly cobalt, which is crucial for the electric vehicle industry. By merging ore-deposit science with big data and scientific computing, KoBold Metals aims to identify new sources of cobalt and support the sustainable supply chain for emerging technologies.

Retiree Income is a company focused on enhancing the financial well-being of retirees and those approaching retirement. The firm has developed retirement income planning software designed to maximize the after-tax income and bequest value for its clients. Utilizing advanced analytic engines, the software offers personalized strategies for income withdrawal and tax efficiency, along with optimal social security claiming options. This approach empowers clients to make informed financial decisions, ultimately improving their ability to manage retirement resources effectively. By emphasizing a smarter and more personalized service model, Retiree Income aims to address the unique financial needs of retirees.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

VerAI Discoveries is an AI-driven mineral asset portfolio company that leverages artificial intelligence and machine learning to identify concealed mineral deposits. By concentrating on underexplored covered terrain in prime mining jurisdictions, VerAI enhances the likelihood of discovering significant mineral deposits while reducing economic risk. The company collaborates with leading industry investors and explorers to develop a global portfolio focused on base and precious metals, thereby unlocking value and contributing to the global supply of critical minerals. Through its innovative platform, VerAI aims to transform the mineral exploration industry by uncovering unique signatures of existing deposits within complex datasets.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies aimed at overcoming cancer treatment resistance and improving patient access to potentially curative options. The company aims to enhance treatment outcomes by addressing the limitations of existing therapies, which currently provide curative benefits to less than half of cancer patients. Its lead program, CRG-022, is a novel CAR T-cell product candidate that targets CD22, a tumor antigen prevalent in many B-cell malignancies. By tackling issues such as limited durability, safety concerns, and supply chain obstacles, Cargo Therapeutics is committed to advancing innovative solutions that make effective cancer treatments more accessible to patients.

Mirion Technologies is a provider of detection, measurement, analysis, and monitoring solutions focused on the safe use of ionizing radiation across various sectors, including nuclear, defense, and medical applications. The company offers a range of products, services, and software designed to meet the stringent regulatory standards and operational requirements of its clients. Its operations are divided into two main segments: Medical and Technologies. The Medical segment focuses on quality assurance in radiation oncology, ensuring patient safety in diagnostic imaging and radiation therapy. The Technologies segment serves the nuclear energy and defense industries, as well as laboratories and scientific research, enabling safe and effective utilization of radiation in critical applications. Mirion Technologies is committed to leveraging its extensive expertise in radiation to support advancements that benefit humanity.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Jetti Resources is a company based in Vancouver, Canada, that specializes in developing hydrometallurgical technology for the extraction of metals from mineral ores. Founded in 2014, Jetti focuses primarily on extracting copper from low-grade primary sulfides, including chalcopyrite, which is the most abundant copper mineral ore. The company has developed a proprietary catalytic technology that enhances copper recovery from vast quantities of ore, addressing significant challenges in mineral processing. This technology integrates with existing heap leaching methods and downstream operations, allowing industrial clients to improve copper yields in a cost-effective and environmentally sustainable manner. Additionally, Jetti's technology is applicable for the extraction of zinc and nickel from sulfide ores, further diversifying its capabilities in mineral processing.

Celonis is a company that specializes in execution management, focusing on optimizing and analyzing business processes across various industries, including production, human resources, and logistics. Its core product, the Celonis Execution Management System (EMS), utilizes advanced process mining technology to enhance productivity and streamline operations. The EMS provides a comprehensive suite of tools and applications, including Celonis Studio, designed for business executives and users to effectively manage execution across analytics, strategy, planning, and automation. By offering unique software solutions, Celonis enables organizations to improve process transparency and efficiency, ultimately unlocking their full execution capacity.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

Cleerly is a healthcare company focused on improving the prevention of heart attacks through innovative digital care pathways. It aims to establish a new standard for coronary artery disease by combining advanced clinical science with cutting-edge artificial intelligence. Cleerly's platform offers a non-invasive approach that quantifies and characterizes plaque buildup in coronary arteries, enhancing the understanding of cardiovascular health. By providing actionable clinical insights, the company enables healthcare providers to better identify at-risk patients and implement early treatment strategies. Ultimately, Cleerly's data-driven solutions aspire to deliver significant value to the healthcare system while improving heart health outcomes for individuals susceptible to heart attacks.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2019, the company utilizes artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By employing machine learning techniques, Delfi Diagnostics develops high-precision, non-invasive tests that aim to detect cancer at a stage when it is most treatable. Their technology enables healthcare professionals to recognize previously unrecognized cancer-associated cell-free DNA fragments, facilitating timely and effective treatment options for patients.

YuLife is a London-based insurance company founded in 2016 that focuses on promoting well-being through its innovative insurance platform. By integrating gamification and behavioral science, YuLife offers life and medical insurance plans that incentivize healthy living. Users are encouraged to engage in activities such as walking and meditation, earning rewards like air miles, vouchers, and gift cards as they pursue a healthier lifestyle. This approach not only supports individual wellness but also helps businesses ensure their employees are insured while fostering a culture of health and motivation. YuLife aims to transform financial products into a force for good, making everyday wellness accessible to all.

Flexe, Inc. operates a cloud-based marketplace that connects organizations seeking additional warehousing and fulfillment services with those that have surplus capacity. Founded in 2013 and headquartered in Seattle, the company specializes in omnichannel logistics solutions, including eCommerce fulfillment, retail distribution, and same-day delivery. Flexe's platform addresses the challenges of inventory overflow and fulfillment needs by creating an open logistics network, allowing clients such as retailers, wholesalers, manufacturers, and logistics companies to optimize their distribution capabilities. By integrating technology and flexible economic models, Flexe enables its customers to enhance their operational efficiency and respond swiftly to market demands.

Senti Biosciences is a clinical-stage biotechnology company specializing in synthetic biology and gene circuit engineering for therapeutic purposes. The company employs its Gene Circuits platform to develop innovative therapies that enhance precision in targeting cancer cells while avoiding damage to healthy cells. Senti Bio's approach involves the use of allogeneic chimeric antigen receptor natural killer (CAR-NK) cells that incorporate its gene circuit technologies, aimed at addressing various oncology indications. Among its product candidates are SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells without harming healthy bone marrow, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences aims to provide effective treatment options for difficult-to-treat diseases through advanced cell and gene therapies.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Convoy, Inc. operates an online marketplace that provides digital freight network services, enabling users to book local and regional trucks on demand for transporting goods, ranging from single pallets to full truckloads. The company offers a mobile application that features real-time shipment tracking, status updates, and ensures on-time deliveries. Founded in 2015 and based in Seattle, Washington, Convoy aims to enhance efficiency in the trucking industry, which is valued at $800 billion and is responsible for significant carbon emissions from empty trucks. By utilizing technology and data, Convoy addresses issues of waste and inefficiency, ultimately saving money for shippers, increasing earnings for drivers, and reducing carbon waste. The platform facilitates instant quotations, online bookings, automated loading suggestions, and online payments, all of which contribute to improved operational efficiency and cost reduction for clients.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the permanent modification of the human genome. This innovative approach enables scientists and clinicians to introduce therapeutic messages into the genome, offering a potential cure for diseases at their source. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics aims to address significant limitations in these areas, enhancing their applicability and effectiveness. Founded by Flagship Pioneering, the company is positioned to transform genetic medicine and improve patient care through its groundbreaking technology.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Cross River Bank, established in 2008 and headquartered in Fort Lee, New Jersey, is a subsidiary of CRB Group, Inc. It offers a range of personal and corporate banking services, including checking, savings, and deposit accounts. The bank specializes in direct lending for commercial real estate projects across the New York, New Jersey, and Connecticut metro areas. Notably, Cross River Bank combines traditional banking with innovative technologies to provide solutions for fintech companies in marketplace lending and payment processing. It focuses on regulatory compliance and consumer protection to deliver secure, API-based banking platforms and products, encompassing lending, payments, risk management, and BaaS offerings, enabling a comprehensive banking experience for its clients.

SandboxAQ is a company that develops artificial intelligence and quantum technology solutions aimed at addressing complex business and scientific challenges. By integrating expertise from multiple disciplines, including physics, computer science, and mathematics, the company creates Large Quantitative Models and AI sensing applications tailored for various industries. Its offerings are designed to provide practical solutions in sectors such as financial services, healthcare, telecommunications, and cybersecurity. Through its innovative software, SandboxAQ enables clients to tackle significant computational challenges and advance their technological capabilities.

PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Rigetti Computing is a full-stack quantum computing company that designs and manufactures quantum-integrated circuits, which are deployed in low-temperature environments. The company develops control systems that perform quantum logic operations and has created software to seamlessly integrate its quantum systems into existing cloud infrastructures. Rigetti is known for its development of the industry's first multi-chip quantum processor, enabling scalable quantum computing systems. Additionally, the company focuses on practical applications of quantum computing, particularly in computational chemistry and machine learning, and has introduced Forest, a comprehensive programming and execution environment for quantum and classical computing. The majority of its revenue is generated from the United States.

Saluda Medical is a commercial-stage medical device company focused on developing innovative treatments for chronic neurological conditions, particularly chronic neuropathic pain. The company utilizes a unique closed-loop neuromodulation platform that senses and measures neural responses to stimulation. This technology automatically adjusts the therapy based on real-time neurophysiological feedback, allowing for personalized treatment tailored to each patient's specific needs. By monitoring the patient's neural fingerprint, Saluda Medical’s devices enable the precise delivery of electrical stimulation, ultimately improving the management of chronic back pain and enhancing patient outcomes.

CelLink Corporation is an innovative company focused on developing flexible conductive backplanes and circuits for power electronics, including applications in batteries, solar panels, light-emitting diodes, and wire harnessing. Founded in 2012 and based in Belmont, California, CelLink manufactures high-conductance, large-area flexible circuits designed to facilitate clean power transmission. Their products integrate essential components such as busing, fusing, and voltage and temperature monitoring into a single circuit, providing customers with efficient solutions for power and data transmission at competitive prices. By offering advanced technology in a growing market, CelLink aims to support the increasing demand for sustainable energy solutions.

Epirus, Inc. is a technology company based in Hawthorne, California, specializing in the design and development of advanced defense systems that utilize artificial intelligence and directed energy. Founded in 2018, the company focuses on creating solid-state, software-defined high-power microwave solutions aimed at countering unmanned aircraft systems and other asymmetric threats. Its flagship product, ELECTROMAGNETIC PULSE, serves as a counter-infrastructure solution that can simultaneously target multiple threats, effectively neutralizing drones and swarms. By integrating AI and machine learning with advanced electronics, Epirus enhances the detection and tracking of objects of interest, offering innovative capabilities in electronic warfare and power management for both defense and commercial sectors.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, that focuses on developing innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Founded in 2018, the company is working on a small-molecule inhibitor designed to target the underlying causes of this progressive lung disease. The treatment aims to not only halt the progression of IPF but also has the potential to reverse its effects, offering healthcare professionals a new avenue for precision treatments in managing terminal conditions. Endeavor BioMedicines strives to improve patient outcomes and enhance quality of life for those affected by this challenging illness.

Eikon Therapeutics, Inc. is a biopharmaceutical company based in Hayward, California, focused on developing innovative treatments for chronic and life-threatening diseases. Founded in 2019, the company employs advanced super-resolution microscopy and live-cell imaging techniques to discover drugs targeting previously intractable proteins. By integrating biology, engineering, and chemistry, Eikon Therapeutics aims to enhance the understanding of cellular processes and improve drug discovery efficiency. Its proprietary platforms allow for the sensitive identification of compound-protein interactions, enabling the direct measurement of how chemical compounds affect individual proteins in live cells. This novel approach seeks to unlock new therapeutic opportunities and expand the company's pipeline of potential medications.

SalioGen Therapeutics is a biotechnology company focused on developing gene therapies for inherited disorders. Utilizing its proprietary Exact DNA Integration Technology (EDIT), the company employs mammal-derived enzymes, known as Saliogase, to facilitate genome engineering. This innovative approach enables the delivery of any size gene through non-viral methods, offering significant advantages in manufacturing and application. SalioGen's technology aims to provide durable, safe, and affordable treatments, potentially transforming the landscape of care for patients with genetic conditions and enhancing the efficiency of cell therapy and biologics manufacturing in the healthcare sector.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

Pardes Biosciences is a clinical-stage biopharmaceutical company focused on addressing significant health challenges, particularly those posed by viral infections. It utilizes modern reversible-covalent chemistry to discover and develop novel oral drug candidates. The company's lead product candidate, PBI-0451, is an oral antiviral designed to treat and prevent infections from SARS-CoV-2, the virus responsible for COVID-19. By reimagining the patient journey, Pardes aims to provide accessible and convenient treatment options for both adult and pediatric patients, ultimately striving to improve health outcomes and respond effectively to global health crises.

Airtable is a cloud-based software company that provides an intuitive online platform for creating and sharing relational databases. The company enables users to build custom applications tailored to their needs, facilitating tasks such as creating flexible checklists, organizing collections or ideas, and managing customer contacts. With a diverse range of templates available, from home improvement projects to inventory management, Airtable caters to various use cases without requiring users to have prior coding experience. The platform is designed to democratize software creation, empowering individuals and business teams alike to develop the tools that best suit their requirements.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Grab Holdings Inc. is a prominent online-to-offline service provider based in Singapore, focusing on mobile technology solutions for transportation across Southeast Asia. Founded in 2012 by Anthony Tan and Tan Hooi Lng, Grab integrates various transportation services through its platform, which includes offerings such as GrabTaxi, GrabCar, GrabHitch, GrabShare, GrabCoach, GrabShuttle, GrabShuttle Plus, GrabFamily, JustGrab, GrabNow, and GrabRental. The company operates in multiple countries, including Singapore, Indonesia, the Philippines, Malaysia, Thailand, Vietnam, and Myanmar. In addition to its headquarters in Singapore, Grab has offices in Seattle, Beijing, Bangalore, Jakarta, and Vietnam, further extending its reach and capabilities within the region.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Farmers Business Network, Inc. is an independent agricultural technology and commerce platform that serves as a farmer-to-farmer network, empowering its members to make informed decisions to enhance the economic viability of their farms. The company advocates for family farmers and ranchers by providing data-driven agronomic insights, facilitating direct purchases from manufacturers, and enabling competitive market opportunities for selling crops. Farmers can leverage the network to share information and access vital resources such as health and crop insurance. With a membership that spans over 80 million acres across the U.S., Canada, and Australia, Farmers Business Network employs over 800 personnel and operates offices in key locations, including San Carlos, California, Chicago, Illinois, Sioux Falls, South Dakota, and its Canadian and Australian headquarters in High River, Alberta, and Perth, respectively.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Color is a healthcare technology company that offers a comprehensive platform for population health management, facilitating equitable and accessible healthcare delivery. The company specializes in large-scale health initiatives, providing solutions that include population genomics programs and high-throughput testing services, such as those for COVID-19. By centralizing essential healthcare capabilities, Color enables businesses, schools, and state public health departments to implement effective preventive health programs, regardless of the geographical distribution of their populations. Its innovative approach addresses various healthcare logistics challenges, streamlining processes related to testing, screening, treatment, and referrals, while creating diverse market opportunities and revenue streams for clinical teams.

Socure Inc. is a provider of digital identity verification solutions, focusing on real-time identity authentication through its Socure ID+ platform. This predictive analytics platform utilizes artificial intelligence and machine learning to authenticate identities by analyzing a multitude of online and offline data sources, including email, phone numbers, addresses, IP addresses, and social media profiles. Socure's offerings include Aida, an AI-driven bot for validating digital identities, Docv, an omnichannel document verification solution, and Sigma Synthetic Fraud, which tackles synthetic identity fraud. The company addresses the needs of various sectors, including software, consulting, and financial firms, through compliance initiatives such as customer identification programs, know your customer requirements, and anti-money laundering measures. Founded in 2012 and headquartered in New York, Socure has established partnerships with key industry players to enhance its service delivery.

Nextdoor, Inc. is a social networking platform based in San Francisco that facilitates local conversations among residents. Founded in 2007, the company aims to foster connections within neighborhoods by allowing users to share recommendations, news updates, and resources while also promoting local businesses and services. Nextdoor enhances community engagement by offering features like the Help Map, which enables neighbors to offer assistance to those in need, particularly during crises such as the Covid-19 pandemic. With a presence in multiple countries, including the United States, the United Kingdom, and several European nations, Nextdoor seeks to create a sense of belonging and support among neighbors, emphasizing the importance of community in people's lives.

Aurora is a self-driving vehicle company providing a platform that brings software and data services to operate passenger vehicles. To move both people and goods, the company develops Aurora Driver, a platform that brings together software, hardware, and data services to operate passenger vehicles, light commercial vehicles, and heavy-duty trucks. Aurora is backed by Amazon and Sequoia, among others, and partners with industry leaders including Toyota, Uber, Volvo, and Paccar. Aurora tests its vehicles in the Bay Area, Pittsburgh, and Dallas. The company has offices in those areas as well as in Bozeman, MT; Seattle, WA; Louisville, CO; and Wixom, MI.

Nuro, Inc. is a technology company based in Mountain View, California, that specializes in the development of self-driving vehicles specifically designed for local goods transportation. Incorporated in 2016, Nuro aims to transform local commerce through its fleet of fully autonomous, electric vehicles that facilitate the delivery of a wide range of products, including food and pharmaceuticals. By enabling retailers to efficiently and safely deliver goods to customers, Nuro enhances the convenience of local commerce and meets the growing demand for autonomous delivery solutions.

Rad Power Bikes LLC, based in Seattle, Washington, is a leading manufacturer and retailer of electric bicycles in North America. Founded in 2015, the company specializes in designing feature-rich e-bikes suitable for both on and off-road use, catering to a diverse range of consumer needs. In addition to its electric bikes, Rad Power Bikes offers a variety of accessories such as bags, fenders, racks, and safety products, as well as replacement parts like batteries and tires. The company operates on a direct-to-consumer model, selling its products primarily through online platforms, which allows it to provide affordable and accessible transportation solutions. With a rapidly expanding workforce exceeding 700 employees, Rad Power Bikes is committed to revolutionizing electric mobility and promoting energy-efficient transportation options.

Oak Hill Advisors L.P. is a privately owned investment management firm based in New York, with additional offices in key global cities. Founded in 1987, the firm specializes in alternative credit management, focusing on leveraged loans, high yield bonds, distressed securities, and turnaround investments. It operates primarily in the North American and European markets, offering services such as private investment funds, fixed income portfolios, and hedge fund management. Oak Hill Advisors employs a fundamental value-oriented strategy centered on credit analysis and active risk management. The firm typically invests between $5 million and $100 million in small to mid-sized companies across various sectors, including energy, natural resources, manufacturing, healthcare, and consumer services. Investments may take the form of debt, equity, or structured products, and the firm seeks to exit through refinancing or asset sales. With significant capital under management, Oak Hill Advisors serves a diverse client base, including pension funds, insurance companies, and family offices.

Trumid Financial LLC is a financial technology company based in New York that specializes in electronic trading solutions for the credit market. Founded in 2014, Trumid operates the Trumid Market Center, an electronic trading network specifically designed for corporate bonds, and offers Trumid Bond Stream, a tool that provides TRACE pricing data. The company focuses on enhancing the credit trading experience by integrating advanced technology with market expertise, facilitating direct access to liquidity and valuable market intelligence for professionals in the corporate bond sector. Additionally, Trumid Labs leverages data science to manage its network and provide bond price lookup services, enabling participants to make informed trading decisions. Trumid operates as a subsidiary of Trumid Holdings LLC.

Honor is a leading senior care network and technology platform that focuses on enhancing the quality of life for older adults and their families. Founded in 2014 by Cameron Ring, Monica Lo, Sandy Jen, and Seth Sternberg in San Francisco, California, Honor has established itself as a pioneer in the home care industry. The company offers expert in-home care services for seniors, leveraging an integrated system of third-party care providers. By combining scalable workforce management with personalized care, Honor enables older adults to live safely and comfortably in their own homes. In 2021, Honor expanded its reach by acquiring Home Instead, enhancing its capabilities through a global network and a relationship-based care model. This strategic move positions Honor to address the evolving needs of aging adults and professional caregivers worldwide.

Coalition, Inc. is an insurance provider based in San Francisco, California, specializing in cyber risk management. Founded in 2017, the company offers a blend of comprehensive insurance coverage and proactive cybersecurity tools tailored for various industries, including healthcare, retail, technology, and more. Coalition's Active Risk Platform equips businesses with automated security alerts, threat intelligence, and expert guidance to enhance their resilience against cyber threats. By integrating risk assessment, security protection, and response capabilities, Coalition enables organizations to effectively mitigate and prevent potential cyber-attacks and associated losses. The company serves clients in the United States and Canada while providing its security solutions globally, supported by prominent global insurers.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Canva, Inc. is a graphic design software provider based in Surry Hills, Australia, established in 2012. The company operates an online platform that enables users to create a variety of visual content, including presentations and social media graphics, using an intuitive drag-and-drop interface. Canva offers a diverse library of layouts, images, photo filters, icons, and fonts, which allows users to personalize their designs without needing advanced software skills. Additionally, Canva provides a plug-in called Canva Button for third-party websites, facilitating graphic creation for their users. The platform serves a wide range of customers, including photographers, illustrators, and designers, with the goal of making design more accessible to everyone.

Snyk Ltd. is a software as a service company that specializes in application security, enabling developers to identify and remediate vulnerabilities within their code and associated components. Founded in 2015 and headquartered in London, Snyk offers a suite of tools designed for modern application development, including Snyk Code for static application security testing, container vulnerability management, and infrastructure as code security solutions. The platform seamlessly integrates into developers' workflows, allowing security teams to collaborate effectively with development teams. Snyk's services encompass monitoring application dependencies for vulnerabilities, ensuring licensing compliance, and providing detailed reports and issue tracking. With a client base of 1,200 organizations, including prominent companies like Google and Salesforce, Snyk empowers developers to build secure applications while enhancing overall security posture and productivity. The company also maintains a strategic partnership with Rapid7, further extending its capabilities in the security landscape.

Checkr, Inc. is a technology-driven company focused on the background check industry, offering a comprehensive range of screening services, including criminal record checks, driving checks, and identity verification. Founded in 2014 and headquartered in San Francisco, California, Checkr utilizes advanced technology and data sources to deliver faster and more efficient background checks compared to traditional providers. The company emphasizes fairness and transparency in hiring, enabling businesses across various sectors, including financial services, healthcare, and staffing, to enhance their hiring processes. Checkr also provides compliance services and security solutions, ensuring a secure and streamlined experience for both employers and candidates. With its innovative platform, Checkr aims to improve the overall applicant experience while supporting companies in navigating the complexities of today's workforce dynamics.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.